The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview
The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) was launched in 2025 to address urgent gaps in supportive care for Canadians with cancer experiencing demoralization syndrome (loss of meaning, dysphoria, disheartenment, helplessness, a sense of failure) and related psychosocial distress. CAN-PACT has six major objectives: (1) to develop a national interdisciplinary research and practice network; (2) to set research priorities through structured stakeholder engagement; (3) to develop and provide PAT training and education for clinicians, researchers, and patients; (4) to pilot test the feasibility of intervention and assessment procedures; (5) to conduct a multi-center, randomized controlled trial of PAT for people with advanced cancer; and (6) to inform and influence healthcare policy on PAT in Canada. We discuss the background and need for PAT in cancer, describe challenges currently limiting its use, and outline CAN-PACT's strategy for building capacity, generating Canadian evidence, and preparing the oncology healthcare environment for potential implementation. This manuscript presents a summary overview of CAN-PACT as a multi-objective research program; detailed protocols for each discrete study component will be published separately as the research program progresses. Through environmental scans, national engagement, targeted training, rigorous research, and ongoing collaboration with policymakers, CAN-PACT aims to enable equitable access to safe, evidence-based PAT for people with advanced cancer in Canada's publicly funded cancer centers.
Authors
- Chantal Savard
- Harvey Max Chochinov (ORCID: https://orcid.org/0000-0003-2656-4704)
- Cláudio N. Soares (ORCID: https://orcid.org/0000-0001-7056-7174)
- Lynda G. Balneaves (ORCID: https://orcid.org/0000-0002-6535-2096)
- Christopher P. Albertyn (ORCID: https://orcid.org/0000-0002-4682-6890)
- Jean Mathews (ORCID: https://orcid.org/0000-0002-9952-7050)
- Wei Tu (ORCID: https://orcid.org/0000-0002-0255-4037)
- Julie M. Deleemans (ORCID: https://orcid.org/0000-0001-8645-0990)
- Alan Bates (ORCID: https://orcid.org/0000-0002-7377-1880)
- Linda E. Carlson (ORCID: https://orcid.org/0000-0002-4411-2085)
- Monnica T. Williams (ORCID: https://orcid.org/0000-0003-0095-3277)
- Margot J. Burnell
- David R. Cléments (ORCID: https://orcid.org/0000-0002-4999-3563)
- Hilary Horlock
- Ron Shore
- Michael McKenzie
- Harriet Richardson
Institutions
- BC Cancer Agency (CA)
- Providence Health Care (CA)
- University of British Columbia (CA)
- University of Ottawa (CA)
- Canadian Cancer Society (CA)
- University of Calgary (CA)
- Queen's University (CA)
- Saint John Regional Hospital (CA)
- CancerCare Manitoba (CA)
- Canadian Patient Safety Institute (CA)
- Kingston Health Sciences Centre (CA)
- University of Manitoba (CA)
- Carleton University (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.3390/curroncol33010007
- Citations
- 1
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.31
Funders
- Fondation Brain Canada
- Alberta Cancer Foundation
- Canada Research Chairs
- Provincial Health Services Authority
- Canadian Institutes of Health Research